Accurately predicting and selecting patients who can benefit from targeted or immunotherapy is crucial for precision therapy. Trophoblast cell surface antigen 2 (Trop2) has been extensively investigated as a pan-cancer biomarker expressed in various tumours and plays a crucial role in tumorigenesis through multiple signalling pathways. Our laboratory successfully developed two 68Ga-labelled nanobody tracers that can rapidly and specifically target Trop2. Of the two tracers, [68Ga]Ga-NOTA-T4, demonstrated excellent pharmacokinetics in preclinical mouse models and a beagle dog. Moreover, [68Ga]Ga-NOTA-T4 immuno-positron emission tomography (immunoPET) allowed noninvasive visualisation of Trop2 heterogeneous and differential expression in preclinical solid tumour models and ten patients with solid tumours. [68Ga]Ga-NOTA-T4 immunoPET could facilitate clinical decision-making through patient stratification and response monitoring during Trop2-targeted therapies.

中文翻译：

---

实体瘤患者 Trop2 的免疫 PET 成像。


准确预测和选择可以从靶向或免疫治疗中受益的患者对于精准治疗至关重要。滋养层细胞表面抗原 2 (Trop2) 作为在多种肿瘤中表达的泛癌生物标志物已被广泛研究，并通过多种信号通路在肿瘤发生中发挥关键作用。我们实验室成功开发了两种68Ga标记的纳米抗体示踪剂，可以快速、特异性地靶向Trop2。两种示踪剂中，[68Ga]Ga-NOTA-T4 在临床前小鼠模型和比格犬中表现出优异的药代动力学。此外，[68Ga]Ga-NOTA-T4免疫正电子发射断层扫描（immunoPET）允许对临床前实体瘤模型和10名实体瘤患者中Trop2异质性和差异性表达进行无创可视化。 [68Ga]Ga-NOTA-T4 免疫PET可以通过Trop2靶向治疗期间的患者分层和反应监测来促进临床决策。